FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385999738> ?p ?o ?g. }

• W4385999738 endingPage "255" @default.
• W4385999738 startingPage "247" @default.
• W4385999738 abstract "Objective: The objective was to compare the safety and efficacy of noncorticosteroid topical treatments for plaque psoriasis. Data Sources: A literature search of the PubMed database was performed (January 1978 to May 2023) using the keywords plaque psoriasis, tapinarof, benvitimod, Vtama, roflumilast, Zoryve, pimecrolimus, tacrolimus, tazarotene, tacalcitol, calcitriol, Vectical, calcipotriene, Dovonex, tacalcitol, vitamin D analogs, salicylic acid, non-corticosteroid topical, Investigator’s Global Assessment, and Physician’s Global Assessment. Study Selection and Data Extraction: Relevant English-language articles and clinical trial data were considered. Data Synthesis: Six noncorticosteroid topical classes for the treatment of plaque psoriasis were selected. The percentage of patients with plaque psoriasis who achieved Investigator’s Global Assessment (IGA) success after 8 weeks of treatment with tacalcitol, calcipotriene/betamethasone dipropionate compound, tazarotene/halobetasol propionate, and roflumilast was 17.9%, 39.9%, 40.7%, and 42.4%, respectively. For 12-week trials of tapinarof and coal tar, 37.4% and 58.2% of patients achieved IGA success, respectively. There were 48% and 71.4% reductions in IGA scores with salicylic acid (12 weeks) and pimecrolimus (4 weeks), respectively. Finally, 66.7% of patients achieved Physician’s Global Assessment success with 8 weeks of tacrolimus. There were no serious adverse events for the noncorticosteroid topicals. Conclusion: Noncorticosteroid topicals are suitable options for patients with plaque psoriasis who would like to avoid topical corticosteroids or have experienced adverse effects from chronic corticosteroid use. Due to treatment duration differences and varied outcome measures, it is unclear which noncorticosteroid topical is most efficacious; however, calcineurin inhibitors appear to exhibit the greatest efficacy. Each topical was efficacious in treating plaque psoriasis and had an adequate safety profile. Despite several treatment options for plaque psoriasis, medication adherence is a limiting factor." @default.
• W4385999738 created "2023-08-20" @default.
• W4385999738 creator A5033809531 @default.
• W4385999738 creator A5045982906 @default.
• W4385999738 creator A5050736172 @default.
• W4385999738 creator A5072010463 @default.
• W4385999738 creator A5092805240 @default.
• W4385999738 date "2023-08-19" @default.
• W4385999738 modified "2023-10-07" @default.
• W4385999738 title "Noncorticosteroid Topical Therapies for the Treatment of Plaque Psoriasis: A Narrative Review" @default.
• W4385999738 cites W1534121531 @default.
• W4385999738 cites W1552422862 @default.
• W4385999738 cites W1964487329 @default.
• W4385999738 cites W1982337794 @default.
• W4385999738 cites W1998116294 @default.
• W4385999738 cites W2000716216 @default.
• W4385999738 cites W2003810928 @default.
• W4385999738 cites W2014298286 @default.
• W4385999738 cites W2018744531 @default.
• W4385999738 cites W2020555111 @default.
• W4385999738 cites W2038934767 @default.
• W4385999738 cites W2044832199 @default.
• W4385999738 cites W2060086598 @default.
• W4385999738 cites W2100105332 @default.
• W4385999738 cites W2101503285 @default.
• W4385999738 cites W2102164031 @default.
• W4385999738 cites W2123514109 @default.
• W4385999738 cites W2160096806 @default.
• W4385999738 cites W2166793660 @default.
• W4385999738 cites W2411955848 @default.
• W4385999738 cites W2521174470 @default.
• W4385999738 cites W2746334295 @default.
• W4385999738 cites W2790525120 @default.
• W4385999738 cites W2924895007 @default.
• W4385999738 cites W2947828030 @default.
• W4385999738 cites W2982429666 @default.
• W4385999738 cites W2991393620 @default.
• W4385999738 cites W3028355101 @default.
• W4385999738 cites W3042678059 @default.
• W4385999738 cites W3045628073 @default.
• W4385999738 cites W3046064855 @default.
• W4385999738 cites W3118633569 @default.
• W4385999738 cites W3137068015 @default.
• W4385999738 cites W3138450947 @default.
• W4385999738 cites W3211277628 @default.
• W4385999738 cites W4200054824 @default.
• W4385999738 cites W4210842125 @default.
• W4385999738 cites W4211077900 @default.
• W4385999738 cites W4211180774 @default.
• W4385999738 cites W4225159578 @default.
• W4385999738 cites W4283591596 @default.
• W4385999738 cites W4296799947 @default.
• W4385999738 cites W73489392 @default.
• W4385999738 doi "https://doi.org/10.1177/87551225231193057" @default.
• W4385999738 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37745732" @default.
• W4385999738 hasPublicationYear "2023" @default.
• W4385999738 type Work @default.
• W4385999738 citedByCount "0" @default.
• W4385999738 crossrefType "journal-article" @default.
• W4385999738 hasAuthorship W4385999738A5033809531 @default.
• W4385999738 hasAuthorship W4385999738A5045982906 @default.
• W4385999738 hasAuthorship W4385999738A5050736172 @default.
• W4385999738 hasAuthorship W4385999738A5072010463 @default.
• W4385999738 hasAuthorship W4385999738A5092805240 @default.
• W4385999738 hasConcept C126322002 @default.
• W4385999738 hasConcept C16005928 @default.
• W4385999738 hasConcept C197934379 @default.
• W4385999738 hasConcept C2776028589 @default.
• W4385999738 hasConcept C2777138892 @default.
• W4385999738 hasConcept C2779134260 @default.
• W4385999738 hasConcept C2779306117 @default.
• W4385999738 hasConcept C2779800615 @default.
• W4385999738 hasConcept C2780564577 @default.
• W4385999738 hasConcept C2909675724 @default.
• W4385999738 hasConcept C2911091166 @default.
• W4385999738 hasConcept C3020604521 @default.
• W4385999738 hasConcept C535046627 @default.
• W4385999738 hasConcept C71924100 @default.
• W4385999738 hasConceptScore W4385999738C126322002 @default.
• W4385999738 hasConceptScore W4385999738C16005928 @default.
• W4385999738 hasConceptScore W4385999738C197934379 @default.
• W4385999738 hasConceptScore W4385999738C2776028589 @default.
• W4385999738 hasConceptScore W4385999738C2777138892 @default.
• W4385999738 hasConceptScore W4385999738C2779134260 @default.
• W4385999738 hasConceptScore W4385999738C2779306117 @default.
• W4385999738 hasConceptScore W4385999738C2779800615 @default.
• W4385999738 hasConceptScore W4385999738C2780564577 @default.
• W4385999738 hasConceptScore W4385999738C2909675724 @default.
• W4385999738 hasConceptScore W4385999738C2911091166 @default.
• W4385999738 hasConceptScore W4385999738C3020604521 @default.
• W4385999738 hasConceptScore W4385999738C535046627 @default.
• W4385999738 hasConceptScore W4385999738C71924100 @default.
• W4385999738 hasIssue "5" @default.
• W4385999738 hasLocation W43859997381 @default.
• W4385999738 hasLocation W43859997382 @default.
• W4385999738 hasOpenAccess W4385999738 @default.
• W4385999738 hasPrimaryLocation W43859997381 @default.
• W4385999738 hasRelatedWork W1574078569 @default.

• next